Fate Therapeutics Stock Price, News & Analysis (NASDAQ:FATE)

$11.76 +1.18 (+11.15 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$11.76
Today's Range$10.22 - $11.84
52-Week Range$2.52 - $11.84
Volume1.06 million shs
Average Volume678,210 shs
Market Capitalization$599.55 million
P/E Ratio-12.38
Dividend YieldN/A
Beta2

About Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics logoFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:FATE
CUSIPN/A
Phone+1-858-8751803

Debt

Debt-to-Equity Ratio0.32%
Current Ratio7.21%
Quick Ratio7.21%

Price-To-Earnings

Trailing P/E Ratio-12.3789473684211
Forward P/E Ratio-12.12
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.40 million
Price / Sales136.26
Cash FlowN/A
Price / CashN/A
Book Value$1.77 per share
Price / Book6.64

Profitability

Trailing EPS($0.95)
Net Income$-33,460,000.00
Net Margins-935.09%
Return on Equity-64.55%
Return on Assets-46.97%

Miscellaneous

Employees66
Outstanding Shares50,980,000

Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics Inc (NASDAQ:FATE) released its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.01. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $0.95 million. Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The business's revenue for the quarter was up .0% compared to the same quarter last year. View Fate Therapeutics' Earnings History.

When will Fate Therapeutics make its next earnings announcement?

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for Fate Therapeutics.

Where is Fate Therapeutics' stock going? Where will Fate Therapeutics' stock price be in 2018?

7 brokerages have issued 12-month target prices for Fate Therapeutics' stock. Their predictions range from $7.00 to $10.00. On average, they anticipate Fate Therapeutics' stock price to reach $7.67 in the next twelve months. View Analyst Ratings for Fate Therapeutics.

What are Wall Street analysts saying about Fate Therapeutics stock?

Here are some recent quotes from research analysts about Fate Therapeutics stock:

  • 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (1/22/2018)
  • 2. HC Wainwright analysts commented, "Early Encouraging Data With FATE-NK 100 in r/r AML at SITC Significant reductions of leukemic blasts observed in two patients. This morning, Fate reported initial clinical data from the ongoing VOYAGE Phase 1 study, which is investigating FATE-NK100 as a monotherapy for the treatment of r/r acute myelogenous leukemia (AML). After a single dose of FATE-NK100, we note that a subject in the second dose cohort (2×10 7 cells/kg) achieved a morphologic leukemia-free state (mLFS). At day 14, a bone marrow biopsy indicated total clearance of leukemic blasts in the marrow. A second patient from the first dose cohort of VOYAGE (1×10 7 cells/kg) had approximately 50% reduction in leukemic blasts. This patient had a tremendous high disease burden (87% blasts in the marrow). The patient that had the total clearance of leukemic blasts in the marrow had approximately 3×10 4 FATE-NK100 cells per mL in the peripheral blood at day 14 following treatment. In the other patient, after two weeks, approximately 76% of NK cells in the peripheral blood were of FATE-NK100 origin. We view these results as promising and look forward to additional data at higher doses as no dose limiting toxicities (DLTs) were reported so far. The next dose cohort is 1×10 8 cells/kg. In the trial, we note that FATE-NK100 cells persisted in both subjects for at least 14 days with a single dose. We believe this will play an important role for upcoming studies where Fate plans to investigate the combination of FATE-NK100 in advanced solid tumors with monoclonal antibody therapy." (11/10/2017)

Who are some of Fate Therapeutics' key competitors?

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the folowing people:

  • William H. Rastetter Ph.D., Independent Chairman of the Board (Age 68)
  • J. Scott Wolchko, President, Chief Executive Officer, Principal Executive Officer, Director (Age 44)
  • John D. Mendlein Ph.D., Vice Chairman of the Board (Age 57)
  • Jim Beitel, Senior Vice President - Corporate Development
  • Daniel D. Shoemaker Ph.D., Chief Scientific Officer (Age 47)
  • John Ferraro, Vice President - Clinical Operations
  • Wendy Levin, Vice President - Clinical Development
  • Walter Grubb, Vice President - Business Development
  • Cindy Tahl J.D., General Counsel
  • Stewart Abbot Ph.D., Chief Development Officer

Who owns Fate Therapeutics stock?

Fate Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (11.84%), Redmile Group LLC (10.72%), BlackRock Inc. (3.35%), 683 Capital Management LLC (1.67%), Endurant Capital Management LP (1.09%) and Geode Capital Management LLC (0.68%). Company insiders that own Fate Therapeutics stock include Chris Storgard, Cindy Tahl, Daniel D Shoemaker and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.

Who sold Fate Therapeutics stock? Who is selling Fate Therapeutics stock?

Fate Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Franklin Resources Inc. and Rhumbline Advisers. Company insiders that have sold Fate Therapeutics company stock in the last year include Cindy Tahl and Daniel D Shoemaker. View Insider Buying and Selling for Fate Therapeutics.

Who bought Fate Therapeutics stock? Who is buying Fate Therapeutics stock?

Fate Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Millennium Management LLC, Monashee Investment Management LLC, Endurant Capital Management LP, Victory Capital Management Inc., J. Goldman & Co LP, 683 Capital Management LLC and Two Sigma Investments LP. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.

How do I buy Fate Therapeutics stock?

Shares of Fate Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of Fate Therapeutics stock can currently be purchased for approximately $11.76.

How big of a company is Fate Therapeutics?

Fate Therapeutics has a market capitalization of $599.55 million and generates $4.40 million in revenue each year. The biopharmaceutical company earns $-33,460,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Fate Therapeutics employs 66 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 General Atomics Ct Ste 200, SAN DIEGO, CA 92121-1140, United States. The biopharmaceutical company can be reached via phone at +1-858-8751803 or via email at [email protected]


MarketBeat Community Rating for Fate Therapeutics (FATE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  314
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Fate Therapeutics (NASDAQ:FATE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.67$7.67$7.20$7.00
Price Target Upside: 10.15% upside10.15% upside65.52% upside70.32% upside

Fate Therapeutics (NASDAQ:FATE) Consensus Price Target History

Price Target History for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ:FATE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018WedbushReiterated RatingOutperform$10.00 -> $7.00MediumView Rating Details
12/18/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$10.00MediumView Rating Details
12/13/2017HC WainwrightReiterated RatingBuy$7.00HighView Rating Details
12/12/2017Raymond James FinancialReiterated RatingBuyMediumView Rating Details
11/2/2017BMO Capital MarketsReiterated RatingBuy$7.00N/AView Rating Details
9/8/2017Leerink SwannReiterated RatingOutperform -> Outperform$7.00MediumView Rating Details
3/18/2017Roth CapitalSet Price TargetBuy$8.00LowView Rating Details
5/10/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Fate Therapeutics (NASDAQ:FATE) Earnings History and Estimates Chart

Earnings by Quarter for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ FATE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.26)N/AView Earnings Details
11/1/2017Q3 2017($0.25)($0.26)$0.95 million$1.03 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.24)($0.23)$1.02 million$1.03 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.21)($0.24)$1.04 million$1.03 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.28)($0.21)$1.06 million$1.03 millionViewN/AView Earnings Details
11/7/2016Q316($0.29)($0.27)$1.05 million$1.03 millionViewListenView Earnings Details
8/8/2016Q216($0.32)($0.29)$1.02 million$1.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.25)($0.29)$0.84 million$1.32 millionViewN/AView Earnings Details
3/3/2016Q415($0.27)($0.26)$0.58 million$1.08 millionViewN/AView Earnings Details
11/3/2015Q315($0.32)($0.24)$0.46 million$1.03 millionViewN/AView Earnings Details
8/5/2015Q215($0.39)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
5/7/2015Q115($0.34)($0.38)ViewListenView Earnings Details
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details
11/11/2014Q3 2014($0.29)($0.30)ViewN/AView Earnings Details
8/12/2014Q214($0.36)($0.30)ViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.34)ViewN/AView Earnings Details
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details
11/13/2013Q3($0.32)($4.81)$0.21 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Fate Therapeutics (NASDAQ:FATE) Earnings Estimates

2018 EPS Consensus Estimate: ($1.02)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.18)($0.18)($0.18)
Q2 20181($0.24)($0.24)($0.24)
Q3 20181($0.28)($0.28)($0.28)
Q4 20181($0.32)($0.32)($0.32)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Fate Therapeutics (NASDAQ:FATE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Fate Therapeutics (NASDAQ FATE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.88%
Institutional Ownership Percentage: 57.60%
Insider Trades by Quarter for Fate Therapeutics (NASDAQ:FATE)
Insider Trades by Quarter for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ FATE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/16/2017Cindy TahlGeneral CounselSell8,091$3.85$31,150.35View SEC Filing  
10/16/2017Daniel D ShoemakerInsiderSell13,225$3.87$51,180.75View SEC Filing  
11/23/2016Chris StorgardInsiderBuy37,593$2.66$99,997.389,090View SEC Filing  
11/23/2016William H RastetterDirectorBuy375,939$2.66$999,997.74View SEC Filing  
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Fate Therapeutics (NASDAQ FATE) News Headlines

Source:
DateHeadline
Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK ... - GlobeNewswire (press release)Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK ... - GlobeNewswire (press release)
globenewswire.com - February 24 at 8:15 AM
Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer ImmunotherapyFate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy
finance.yahoo.com - February 23 at 8:22 AM
Fate Therapeutics Inc (FATE) Receives Consensus Recommendation of "Buy" from BrokeragesFate Therapeutics Inc (FATE) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 23 at 2:00 AM
41 Biggest Movers From Yesterday - Benzinga41 Biggest Movers From Yesterday - Benzinga
www.benzinga.com - February 22 at 8:21 AM
Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors - GlobeNewswire (press release)Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors - GlobeNewswire (press release)
globenewswire.com - February 20 at 8:16 AM
Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid TumorsFate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors
finance.yahoo.com - February 20 at 8:16 AM
$1.02 Million in Sales Expected for Fate Therapeutics Inc (FATE) This Quarter$1.02 Million in Sales Expected for Fate Therapeutics Inc (FATE) This Quarter
www.americanbankingnews.com - February 14 at 2:24 AM
Fate Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceFate Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 13 at 9:58 AM
Fate Therapeutics Inc (FATE) Expected to Announce Earnings of -$0.24 Per ShareFate Therapeutics Inc (FATE) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - February 12 at 7:20 PM
With A -16.46% Earnings Drop, Is Fate Therapeutics Inc’s (NASDAQ:FATE) Performance A Concern?With A -16.46% Earnings Drop, Is Fate Therapeutics Inc’s (NASDAQ:FATE) Performance A Concern?
finance.yahoo.com - February 6 at 9:28 AM
Fate Therapeutics Inc (FATE) Given Consensus Rating of "Buy" by AnalystsFate Therapeutics Inc (FATE) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - January 29 at 1:46 AM
-$0.25 EPS Expected for Fate Therapeutics Inc (FATE) This Quarter-$0.25 EPS Expected for Fate Therapeutics Inc (FATE) This Quarter
www.americanbankingnews.com - January 26 at 9:10 PM
Fate Therapeutics (FATE) Downgraded to "Hold" at Zacks Investment ResearchFate Therapeutics (FATE) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 22 at 11:54 PM
Equities Analysts Offer Predictions for Fate Therapeutics Incs FY2022 Earnings (FATE)Equities Analysts Offer Predictions for Fate Therapeutics Inc's FY2022 Earnings (FATE)
www.americanbankingnews.com - January 22 at 3:24 PM
Fate Therapeutics (FATE) Upgraded to "Buy" at Zacks Investment ResearchFate Therapeutics (FATE) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 19 at 11:32 PM
Fate Therapeutics (FATE) Stock Rating Reaffirmed by WedbushFate Therapeutics (FATE) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - January 18 at 12:58 PM
 Analysts Expect Fate Therapeutics Inc (FATE) Will Post Quarterly Sales of $1.02 Million Analysts Expect Fate Therapeutics Inc (FATE) Will Post Quarterly Sales of $1.02 Million
www.americanbankingnews.com - January 11 at 3:06 AM
Fate Therapeutics (FATE) Lifted to "Buy" at Zacks Investment ResearchFate Therapeutics (FATE) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 9 at 11:20 PM
Zacks: Brokerages Expect Fate Therapeutics Inc (FATE) Will Post Earnings of -$0.25 Per ShareZacks: Brokerages Expect Fate Therapeutics Inc (FATE) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - January 9 at 7:06 PM
Fate Therapeutics Inc (FATE) Receives Average Recommendation of "Buy" from AnalystsFate Therapeutics Inc (FATE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 4 at 2:26 AM
Fate Therapeutics (FATE) Jumps: Stock Rises 5.7%Fate Therapeutics (FATE) Jumps: Stock Rises 5.7%
finance.yahoo.com - December 28 at 12:45 PM
 Brokerages Anticipate Fate Therapeutics Inc (FATE) to Post -$0.26 Earnings Per Share Brokerages Anticipate Fate Therapeutics Inc (FATE) to Post -$0.26 Earnings Per Share
www.americanbankingnews.com - December 24 at 9:20 AM
Fate Therapeutics (FATE) Lifted to Hold at ValuEngineFate Therapeutics (FATE) Lifted to Hold at ValuEngine
www.americanbankingnews.com - December 23 at 4:14 PM
ETFs with exposure to Fate Therapeutics, Inc. : December 21, 2017ETFs with exposure to Fate Therapeutics, Inc. : December 21, 2017
finance.yahoo.com - December 21 at 5:16 PM
The Fate Therapeutics Thesis: How Does It Hold Up To Scrutiny? - Seeking AlphaThe Fate Therapeutics Thesis: How Does It Hold Up To Scrutiny? - Seeking Alpha
seekingalpha.com - December 19 at 9:32 AM
Fate Therapeutics: Updates To Thesis - Seeking AlphaFate Therapeutics: Updates To Thesis - Seeking Alpha
seekingalpha.com - December 19 at 9:32 AM
Piper Jaffray Companies Begins Coverage on Fate Therapeutics (FATE)Piper Jaffray Companies Begins Coverage on Fate Therapeutics (FATE)
www.americanbankingnews.com - December 18 at 7:42 PM
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters ... - GlobeNewswire (press release)Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters ... - GlobeNewswire (press release)
globenewswire.com - December 16 at 5:13 PM
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesFate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - December 15 at 5:51 PM
Fate Therapeutics ProTmune shows positive effect in early-stage study; shares up 5% - Seeking AlphaFate Therapeutics' ProTmune shows positive effect in early-stage study; shares up 5% - Seeking Alpha
seekingalpha.com - December 14 at 9:40 AM
Fate Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)Fate Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - December 14 at 9:40 AM
Fate Therapeutics Announces Pricing of Public Offering of Common ... - GlobeNewswire (press release)Fate Therapeutics Announces Pricing of Public Offering of Common ... - GlobeNewswire (press release)
globenewswire.com - December 14 at 9:40 AM
Fate Therapeutics (FATE) Buy Rating Reiterated at HC WainwrightFate Therapeutics' (FATE) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - December 13 at 6:22 PM
Fate Therapeutics (FATE) Reports Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune & Initiation of Phase 2 StageFate Therapeutics (FATE) Reports Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune & Initiation of Phase 2 Stage
www.streetinsider.com - December 13 at 9:50 AM
Fate Therapeutics Announces Pricing of Public Offering of Common StockFate Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - December 13 at 9:50 AM
Fate Therapeutics Announces Proposed Public Offering of Common StockFate Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - December 12 at 5:43 PM
Fate Therapeutics (FATE) Buy Rating Reiterated at Raymond James FinancialFate Therapeutics' (FATE) Buy Rating Reiterated at Raymond James Financial
www.americanbankingnews.com - December 12 at 12:46 PM
Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 StageFate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage
finance.yahoo.com - December 12 at 9:59 AM
Fate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered ... - StreetInsider.comFate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered ... - StreetInsider.com
www.streetinsider.com - December 11 at 5:29 PM
Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling ... - GlobeNewswire (press release)Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling ... - GlobeNewswire (press release)
globenewswire.com - December 11 at 5:29 PM
Fate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered Master Pluripotent Cell LineFate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered Master Pluripotent Cell Line
www.streetinsider.com - December 11 at 10:17 AM
Fate Therapeutics, Inc. (FATE) Given Average Rating of "Buy" by AnalystsFate Therapeutics, Inc. (FATE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 10 at 1:52 AM
Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell ImmunotherapyFate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy
finance.yahoo.com - December 9 at 5:10 PM
Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian CancerFate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer
finance.yahoo.com - December 8 at 5:10 PM
Zacks: Brokerages Expect Fate Therapeutics, Inc. (FATE) Will Announce Quarterly Sales of $1.02 MillionZacks: Brokerages Expect Fate Therapeutics, Inc. (FATE) Will Announce Quarterly Sales of $1.02 Million
www.americanbankingnews.com - December 8 at 6:32 AM
Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock? - NasdaqAre Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock? - Nasdaq
www.nasdaq.com - December 6 at 5:18 PM
Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer ImmunotherapiesFate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer Immunotherapies
finance.yahoo.com - December 6 at 9:42 AM
ASH: BPMC To Make A Mark; FATE So Far, So Good; Watch Out For SYRS, BIVVASH: BPMC To Make A Mark; FATE So Far, So Good; Watch Out For SYRS, BIVV
www.rttnews.com - December 5 at 10:15 AM
Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?Are Options Traders Betting on a Big Move in Fate Therapeutics (FATE) Stock?
finance.yahoo.com - December 5 at 10:15 AM
ValuEngine Lowers Fate Therapeutics (FATE) to SellValuEngine Lowers Fate Therapeutics (FATE) to Sell
www.americanbankingnews.com - December 3 at 3:12 PM

SEC Filings

Fate Therapeutics (NASDAQ:FATE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Fate Therapeutics (NASDAQ:FATE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Fate Therapeutics (NASDAQ FATE) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.